Clinical trial NCT02737384: Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)
Official title: Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID): Selective Depletion of Naive Cells From the Graft
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Combined Immunodeficiencies
Keywords: Combined immunodeficiencies
hematopoietic stem cell transplantation
CD45RA
primitive immunodeficiencies
pediatric transplantation
CD45RA depletion
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2016-04-13
Enrollment: 4
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate selective depletion of naïve CD45RA+ T cells from allogenic peripheral blood stem cell graft in children transplanted for combined immune deficiency. The aims of this procedure are to prevent graft versus host disease (GVHD) while preserving anti-infectious response from donor memory T lymphocytes.

Detailed description: Combined immunodeficiencies (CIDs) are an heterogeneous group of primitive immunodeficiency (PID), which affect T cells development, function or both. These inherited conditions can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). These procedures have a high risk of morbidity and mortality such a graft versus host disease (GVHD), rejection of the graft and serious infections, especially in this population of children with PID. GVHD is more frequent and severe if the donor is not an identical sibling and/or presents an HLA-mismatch. GVHD requires high immunosuppression as prevention and treatment, and therefore impedes immunity against infections.

In vitro and animal models suggest that GVHD is mediated by naïve T cells. The aim of this study is to decrease the rate and severity of GVHD after selective depletion of naïve CD45RA+ T cells from allogeneic hematopoietic stem cell grafts in patients with CIDs with high risk of severe GVHD, and to preserve immunity against pathogens in a population with high vulnerability to infections.

The project aims is, first, to show improvement of rejection-free and GVH-free survival 12 months post-transplant, and secondly, to show the decrease of viral infection, and assess immune reconstitution kinetic and quality and specific antiviral responses, after a engraftment with naïve cell depleted allograft.

Eligibility criteria: Inclusion Criteria:

* Patient from 12 months to 18 years
* Combined immunodeficiencies with known molecular diagnosis or if unknown, corresponding of p-CID study's definition
* Hematopoietic stem cell Transplantation planned with one of the following donors :
* sibling with 1 or 2 HLA antigens mismatch
* parent 10/10 or 9/10 identical
* unrelated donor: 10/10 or 9/10 identical
* Consent form signed by the child's legal guardian
* Patient using effectiveness contraception during this trial
* Affiliated or beneficiary of a health insurance regimen

Exclusion Criteria:

* Wiskott-Aldrich syndrome
* Ongoing pregnancy
* Positive HIV PCR
* Contraindication for hematopoetic stem cell transplantation
* Geno-identical donor in the siblings
* hematopoetic stem cell transplantation antecedent

Primary outcomes:
measure: Number of death
timeFrame: 12 months after the transplantation
measure: Number of graft rejection
timeFrame: 12 months after the transplantation
measure: Number of graft versus host disease (GVHD) grade III or IV
timeFrame: 12 months after the transplantation
Secondary outcomes:
measure: Need of antiviral treatment
timeFrame: 12 months after the transplantation
measure: T Lymphocyte proliferations to phytohemagglutinin (PHA)
timeFrame: 12 months after the transplantation
measure: Proportion of T CD4 and CD8 lymphocytes specific of cytomegalovirus, Epstein Barr virus and adenovirus
timeFrame: 12 months after the transplantation
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Necker-Enfants Malades
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Marina CAVAZZANA, MD, PhD
role: STUDY_CHAIR
References:
citation: Touzot F, Neven B, Dal-Cortivo L, Gabrion A, Moshous D, Cros G, Chomton M, Luby JM, Terniaux B, Magalon J, Picard C, Blanche S, Fischer A, Cavazzana M. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study. J Allergy Clin Immunol. 2015 May;135(5):1303-9.e1-3. doi: 10.1016/j.jaci.2014.08.019. Epub 2014 Oct 3.